본문으로 건너뛰기
← 뒤로

NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.

1/5 보강
Leukemia & lymphoma 📖 저널 OA 8.7% 2022: 1/1 OA 2025: 2/55 OA 2026: 14/137 OA 2022~2026 2026 Vol.67(2) p. 342-348
Retraction 확인
출처

Calvillo CD, Cardenas Castro V, Shim KG, Arribas M, Kirsch I, Fonseca R

📝 환자 설명용 한 줄

We report on a series of three patients diagnosed with secondary acute lymphoblastic leukemia (sALL) following treatment for multiple myeloma (MM) where serial, commercially available, next-generation

이 논문을 인용하기

↓ .bib ↓ .ris
APA Calvillo CD, Cardenas Castro V, et al. (2026). NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.. Leukemia & lymphoma, 67(2), 342-348. https://doi.org/10.1080/10428194.2025.2586084
MLA Calvillo CD, et al.. "NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.." Leukemia & lymphoma, vol. 67, no. 2, 2026, pp. 342-348.
PMID 41257444 ↗

Abstract

We report on a series of three patients diagnosed with secondary acute lymphoblastic leukemia (sALL) following treatment for multiple myeloma (MM) where serial, commercially available, next-generation sequencing (NGS) based tracking of measurable residual disease (MRD) using the clonoSEQ assay provided valuable clinical insight. Each of the patients in this series had been treated for their MM with regimens that had included autologous stem cell transplantation following high dose melphalan chemotherapy and had been on maintenance treatment with the immunomodulatory drug lenalidomide for at least one year.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반